BioSpace News Archive

DiA Imaging Analysis Ltd. (DiA), a leading provider of AI-powered ultrasound analysis solutions today announced that it has partnered with SonoScape Medical Corporation (300633.SZ), a leading developer and manufacturer of ultrasound systems.

Cardea, a complete open-source ecosystem for the exchange of privacy-preserving digital health credentials has been accepted as a Linux Foundation Public Health project.

Truveris today announced the recent addition of two industry veterans to key leadership positions within the company’s rapidly expanding commercial team: Joanne Biscardi has joined the Company as Senior Vice President, Life Sciences; and Michael Napolitano has joined as Senior Vice President, Payer Sales

CB Therapeutics raises Series A round with re.Mind Capital and accelerates its manufacturing and research of cannabinoids, tryptamines, and other therapeutics.

TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its abstract featuring data from the Company’s investigational therapy, SM-88, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4-8, 2021.

EDGe Surgical, Inc., a company focused on developing and manufacturing smart orthopedic and spine surgical instruments, announced today that it has received a CE Certificate of Conformity from its notified body permitting CE mark of the company’s EDG® Ortho 65mm single-use electronic depth gauge in the European Union market.

IDEOlogy Health and Texas Oncology announced today that the two companies have entered a formal agreement to collaborate on expanding and enhancing medical education for Texas Oncology physicians.

CIC Health and Quest Diagnostics (NYSE:DGX) today announced a collaboration that will help more schools safely return to in-person learning by greatly increasing COVID-19 testing logistics and lab capacity across the country.

- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication

An estimated 3 to 10 million patients in the USA exhibit debilitating symptoms of Post-Acute Sequelae of SARS-CoV-2